Dataset Information

Placenta_NUC_UT

ABSTRACT: Placenta Nuclear Fraction - UT

INSTRUMENT(S): LCQ DECA XP

ORGANISM(S): Mus Musculus

SUBMITTER: Andrew Emili

PROVIDER: PAe000367 | PeptideAtlas |

REPOSITORIES: PeptideAtlas

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	PAe000367_4950_search.params.tar.gz	Other
	PAe000367_4950_searchdatabase_tandem.fasta	Fasta
	PAe000367_4950_tandem.params	Other
	PAe000367_RAW_201104200828.tar.gz	Other
	PAe000367_README	Other

Items per page:

1 - 5 of 11

Similar Datasets

Project description:Androgen receptor (AR)-targeting prostate cancer drugs, which are predominantly competitive ligand binding domain (LBD)-binding antagonists, are inactivated by common resistance -mechanisms. It is important to develop next-generation mechanistically-distinct drugs to treat castration- and drug- resistant prostate cancers. Here, we describe a second-generation AR pan-antagonist (UT-34) that degrades the AR and AR splice variants. UT-34 inhibits the wild-type and LBD mutant ARs comparably and inhibits the in vitro proliferation and in vivo growth of enzalutamide-sensitive and resistant prostate cancer xenografts. In preclinical models, UT-34 induced the regression of enzalutamide-resistant tumors at doses when the AR is degraded; but, at lower doses when the AR is just antagonized, it inhibits, without shrinking, the tumors. This indicates that degradation might be a prerequisite for tumor regression. Mechanistically, UT-34 promotes a conformation that is distinct from the LBD-binding competitive antagonist, enzalutamide, and degrades the AR through the ubiquitin proteasome mechanism. UT-34 has a broad safety margin and exhibits no cross-reactivity with G-Protein Coupled Receptor, kinase, and nuclear receptor family members. Collectively, UT-34 exhibits the properties necessary for a next-generation prostate cancer drug. MR49F cells (n=3-4/group) were maintained in charcoal-stripped serum containing medium for 48 hours and treated with vehicle, 0.1 nM R1881, or 10 uM of UT-34 in combination with 0.1 nM R1881. Twenty four hours after treatment, the cells were harvested, RNA was isolated and expression of genes was measured using microarray (Affymetrix Clarion S) UT-34 is a selective androgen receptor degrader that degrades and antagonizes the AR. UT-34 binds to the AF-1 domain of the AR and degrades the AR through ubiquitin proteasome pathways. The transcriptome study was performed to evaluate the ability of UT-34 to antagonize the enzalutamide-resistant AR function.

Dataset Information

Placenta_NUC_UT

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets